In 2015, Alere, now Abbott, introduced a commercial instrument free Tuberculosis (TB) lipoarabinomannan (LAM) lateral flow assay test (TB LAM) that is cheaper and faster than other available TB diagnostic tests.
In 2019, the World Health Organization (WHO) issued guidelines recommending TB LAM to assist in diagnosis of TB in people living with HIV (PLHIV) for both inpatient and outpatient settings
Given TB LAM’s significant potentially for early identification of TB and improved linkage to care – especially in lower-level decentralized settings, CHAI has strongly advocated for implementation and uptake of TB LAM in line with WHO guidance as part of the package of care for people living with Advanced HIV Disease (AHD).
This document summarizes implementation challenges, lessons learned, and recommendions across countries implmenting TB LAM.
Comments